MacroGenics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

MacroGenics, a clinical-stage biopharmaceutical company focused on cancer therapies, has announced its participation in several investor conferences in November and December 2020. Key events include the Credit Suisse Annual Virtual Healthcare Conference on November 10, the Stifel 2020 Virtual Healthcare Conference on November 17, and the Evercore ISI HealthCONx Virtual Conference on December 2. Each event will involve one-on-one meetings and presentations by management. Webcasts of the conferences will be available for 30 days on MacroGenics' Investor Relations webpage.

ROCKVILLE, MD, Nov. 09, 2020 (GLOBE NEWSWIRE) --  

MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in November and December:

• Credit Suisse 29^th Annual Virtual Healthcare Conference. MacroGenics’ management will participate in one-on-one meetings and provide a corporate overview on November 10, 2020 at 2:45 PM ET.
• Stifel 2020 Virtual Healthcare Conference. MacroGenics’ management will participate in one-on-one meetings and participate in a fireside chat with the analyst on November 17, 2020 at 10:40 AM ET.
• SVB Leerink Oncology 1x1 Day. MacroGenics’ management will participate in one-on-one meetings on November 19, 2020.
• Evercore ISI 3^rd Annual HealthCONx Virtual Conference. MacroGenics’ management will participate in one-on-one meetings and participate in a fireside chat with the analyst on December 2, 2020 at 3:55 PM ET.

Webcasts of the above presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain archived replays of these webcasts on its website for 30 days after each conference.

About MacroGenics, Inc.
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

###

FAQ

When will MacroGenics participate in investor conferences?

MacroGenics will participate in investor conferences on November 10, November 17, November 19, and December 2, 2020.

What is the focus of the conferences MacroGenics is attending?

The conferences focus on healthcare, specifically regarding innovations in cancer therapies.

How can I access the webcasts of MacroGenics' presentations?

Webcasts can be accessed under 'Events & Presentations' on the Investor Relations section of MacroGenics' website.

What is the stock symbol for MacroGenics?

The stock symbol for MacroGenics is MGNX.

What type of company is MacroGenics?

MacroGenics is a clinical-stage biopharmaceutical company specializing in monoclonal antibody-based therapeutics for cancer treatment.